PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Sponaas, Anne Marit ^a   Moharrami, Neda Nejati ^a   Feyzi, Emadoldin ^a,b   Standal, Therese ^a   Rustad, Even Holth ^a,b   Waage, Anders ^a,b   Sundan, Anders ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD141 ANTIGEN; CD303 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN;

ARTICLE; BONE MARROW; CELL SUBPOPULATION; CLINICAL ARTICLE; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MYELOID DENDRITIC CELL; MYELOMA; PLASMA CELL; PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; METABOLISM; MULTIPLE MYELOMA;

ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; MULTIPLE MYELOMA; PLASMA CELLS;

EID: 84948668396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139867     Document Type: Article

References (17)

1. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26: 677-704. doi: 10.1146/annurev.immunol.26.021607.090331 PMID: 18173375
2. Nguyen LT, Ohashi PS (2015) Clinical blockade of PD1 and LAG3-potential mechanisms of action. Nat Rev Immunol 15: 45-56. doi: 10.1038/nri3790 PMID: 25534622
3. Quezada SA, Peggs KS (2013) Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer 108: 1560-1565. doi: 10.1038/bjc.2013.117 PMID: 23511566
4. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, et al. (2007) Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110: 296-304. PMID: 17363736
5. Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, et al. (2013) Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 27: 464-472. doi: 10.1038/leu.2012.213 PMID: 22828443
6. Paiva B, Azpilikueta A, Puig N, Ocio EM, Sharma R, et al. (2015) PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia.
7. Ray A, Das DS, Song Y, Richardson P, Munshi NC, et al. (2015) Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia.
8. Lesokhin AM, Ansell, S.M., Armand, P., Scott, E.C., Halwani, A., Gutierrez, M., Millenson, M.M., Cohen, A.D., Schuster, S.J., Lebovic, D., Dhodapkar, M.V., Avigan, D., Chapuy, B., Ligon, A.H., Scott J. Rodig, S.J., Cattry, D., Zhu, L., Grosso, J.F., Kim, S.Y., Shipp, M.A., Borrello, I., and Timmerman, J. (2014) Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies 56th ASH Annual Meeting and Exposition.
9. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369: 122-133. doi: 10.1056/NEJMoa1302369 PMID: 23724867
10. Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449: 419-426. PMID: 17898760
11. Collin M, McGovern N, Haniffa M (2013) Human dendritic cell subsets. Immunology 140: 22-30. doi: 10.1111/imm.12117 PMID: 23621371
12. Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V (2011) Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol 29: 163-183. doi: 10.1146/annurev-immunol-031210-101345 PMID: 21219184
13. Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, et al. (2010) Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 207: 1261-1271. doi: 10.1084/jem.20092618 PMID: 20479117
14. Crozat K, Guiton R, Guilliams M, Henri S, Baranek T, et al. (2010) Comparative genomics as a tool to reveal functional equivalences between human and mouse dendritic cell subsets. Immunol Rev 234: 177-198. doi: 10.1111/j.0105-2896.2009.00868.x PMID: 20193019
15. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, et al. (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology 15: e538-e548. doi: 10.1016/S1470-2045(14)70442-5 PMID: 25439696
16. Meier A, Bagchi A, Sidhu HK, Alter G, Suscovich TJ, et al. (2008) Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. AIDS 22: 655-658. PMID: 18317010
17. Gilliet M, Cao W, Liu YJ (2008) Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 8: 594-606. doi: 10.1038/nri2358 PMID: 18641647